increase in the incidence of CDI occurred, and approximately two-thirds of patients that suffered CDI did so during hospitalization despite being admitted for other reasons. 10
Financial cost There are scant data on the financial cost of CDI in Poland; however, the potential cost of Clostridium difficile-associated diarrhea in Europe was estimated at €3000 million per year in 2008 and predicted to double over the next 40 years. 11 In 2010, Ghantoji et al 12 demonstrated that non-United States-based studies indicated a cost ranging from $5243 to $8570 for each case of primary CDI, and $13 655 for each case of recurrent CDI (rCDI).
12
In 2015, Kwon et al 13 reported a relatively low mortality rate associated with CDI previously compared with current statistics and an annual cost for acute care alone within the United States attributable to CDI ranging from $1.2 to $5.9 billion. Comparatively, in a review of literature published in 2012, McGlone et al 14 determined a median cost of $31 421 to account for hospital, societal, and third-party payer costs related to CDI. current treatment of Clostridium difficile infection Several factors influence the treatment of CDI, although mild cases are generally treated with metronidazole, and severe cases-with vancomycin (and more recently, with fidaxomicin). 15 While these antibiotics may resolve the first infection in 70% to 78% of the cases, given the known mortality, a good case can be made for patients to have earlier access to FMT after even a single recurrence of CDI. 16, 17 Although alternative antimicrobial treatment options targeting CDI have been used, it is logical to avoid the drugs that originally contributed to the CDI problem and repair the gut microflora deficiency with healthy microbiota. 16 The use of FMT for CDI is well documented although such variables as donor recruitment, formulation of fecal suspension, delivery route, and infusion frequency vary.
18-21 A recent randomized clinical trial compared the efficacy of vancomycin against FMT via colonoscopy using homogenized stool in saline. The trial was halted at the 1-year interim analysis. 22 In 90% of the patients receiving FMT, diarrhea symptoms resolved compared with only 26% of the patients receiving vancomycin. 22 Innovative in this trial was the recurrent use of FMT after the failure of the first infusion in 2 patients with pseudomembraneous colitis (PMC). The protocol was amended to 1 FMT every 3 days until colitis resolved. Recurrent PMC sufferers achieved a cure with multiple infusions.
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Similarly, in Poland, Grzesiowski et al 5 achieved a cure rate in 55 of 62 patients with rCDI (88.7%), with 76.5% cured after the first; 14.5%, after the second; and the remaining 9%, after the third nasogastric infusion.
5 It should be noted that in comparisons of administration routes of FMT for CDI, Gough et al 20 determined that for CDI treatment, "enema" or "rectal catheter" administration ineffective, the composition of the gut microbiome is known to be abnormal with deficiencies in Firmicutes and Bacteroidetes. 3 Such patients respond well to fecal microbiota transplantation (FMT), achieving cure in more than 90% of cases with a single infusion, which also results in the restoration of microbiota abnormalities. 3 The rapid uptake of FMT in Australia, then the United States, and now Europe has provided the clinician with an inexpensive, rapid, and highly efficacious cure of relapsing CDI. Doctors and clinics performing FMT can even be found listed on the Internet, for example, thepowerofpoop.com. 4 The epidemic of CDI has accelerated the broader use of FMT, the success of which has led to research in the non-CDI indications such as inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), among others. This review attempts to acquaint the reader with the current state-of-the-art uses of FMT and emerging FMT products and looks into the future evolution of this field.
Focusing on Poland To demonstrate a local context, figures from Europe indicate that mortality from CDI reaches approximately 40 000 cases annually, indicating that the situation is similar to that in the United States and that the rapid rise in the incidence of CDI in Poland has now reached approximately 11 500 hospitalized cases in 2013.
5 Further publications confirm the gravity of this infection. An abstract analyzing 12 randomly selected hospitals and microbial laboratories throughout Poland determined the mean incidence of CDI in Polish hospitals to be 3.6 per 100 000 in 2011 and 7.1 per 100 000 in 2012.
6
Pituch et al, 7 who utilized data from 13 participating centers, determined the rate of incidence for CDI to be 3668 per 10 000 patients admitted to the hospital in 2011 (tAbLe 1).
More robust figures relating to CDIs occurring in Poland before 2013 are difficult to assess because the Polish National Institute of Public Health only began to publish CDI-specific figures in 2013. Before this, they would have fallen under the published title of "other bacterial intestinal infections" as "total", "specified", or "unspecified", making the role of CDI in said incidences impossible to determine. Obtainable data report an incidence of 12.3 and 16.7 per 100 000 citizens in Poland in 2013 and 2014, respectively (with 4738 and 6425 corresponding cases, respectively).
8,9 Indices relating to any CDI analysis are most likely underreported, considering that individuals suffering mild CDI may not seek treatment.
A study performed by utilizing data from the Polish University Hospital in Krakow between 2008 and 2014 analyzed 1009 individuals, with 78% of patients suffering CDI once and 22% of patients suffering CDI more than once; 2.4% of the patients died within 14 days of CDI confirmation, and mortality rates were 12.9% in medical wards, 5.6% in surgical wards, and 27.7% in intensive care units. From 2008 to 2012, a 6.5-fold product be developed that can obtain the high cure rates associated with standard FMT treatments, be easily transportable, and generally palatable to the recipient. The Boston-based company, OpenBiome, is a not-for-profit organization that distributes throughout the United States frozen fecal suspension for FMT at low cost, yet it ensures the highest donor stool quality. Their product is used by gastroenterologists in numerous clinics and hospitals.
For these reasons, we believe the future of CDI treatment will utilize donor stool that has been filtered to remove all but the microbiota and a substantial amount of water content via lyophilization (freeze-drying) with the resulting component (largely fecal microbiota) being a powder containing the full spectrum microbiota (FSM). This would be encapsulated and could be immediately administered as an oral medication or could be stored for protracted periods and remain viable without refrigeration far longer than fresh or frozen FMT. The authors at the Centre for Digestive Diseases (CDD) are currently analyzing FSM capsules to determine optimal long-term storage conditions. 28 Such an optimized product would do away with transport issues, the discomfort associated with fecal enema infusions, and minimize the 'Ick' factor of handling human stool. 29 Even without encapsulated FSM, product acceptance of FMT has grown. 29 Jiang et al 30 sent questionnaires to gastroenterologists and infectious disease specialists, and of the 89 responses, the majority of both cohorts were supportive of a local fecal transplant (FT) clinic (64% and 69%, respectively), and a large majority indicated they would refer patients to a newly developed local FT center (89% and 81%, respectively). 30 As FMT progresses to using a prescribed medication avoiding the need for enema administrations, the need for specialized FT clinics and hospital departments could become a thing of the past.
Anecdotally, the 'Ick' factor associated with FMT has been less of an issue when referring to patients desperate for treatment. 29 Even though this is likely the case with the vast majority of patients who do not respond to initial antibiotic treatments, offering patients a short course of tasteless/odorless pills for the treatment of CDI rather than an enema is a major improvement on FMT therapeutics.
Data surrounding lyophilized FSM are scant, although our group at the CDD has presented an abstract showing the indices comparing whole cell count and viable cell count of FSM in the form of frozen FMT and lyophilized FMT. 31 Additionally, Jiang et al 32 have recently completed an analysis in which fresh, frozen, and lyophilized FMT were delivered colonoscopically into patients suffering from rCDI, with resulting responses considered successful and each format of FMT considered equally effective. Jiang et al 32 also indicated the value of expanding testing to lyophilized encapsulated FMT.
of FMT was superior to "gastroscope and nasojejunal tube" with the respective values of 95.4%, 95.6%, and 76.4%. Additionally, Postigo and Kim compared colonoscopic and nasogastric administration for CDI from 12 published studies and reported a cure rate of 85.3% for nasogastric and 93.2% for colonoscopic infusion. 23 The findings of Grzesiowski et al 5 are particularly important as they teach us to design CDI treatments to be multiple rather than single infusions seen in most CDI trials, in order to build an expectation of cure approaching 100%.
Moving away from infused fecal suspensions, a preliminary study demonstrated the effectiveness of frozen encapsulated FMT against refractory CDI. Despite utilizing a sample size of only 20 patients, 90% were cured of diarrhea. No significant adverse events occurred attributed to FMT capsules.
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The outcome and long-term follow-up of patients has also shown FMT to be not only highly effective but also surprisingly free of significant adverse events and long-term complications. 25 Apart from the upsurge of nosocomial CDI, this infection has increasingly become contracted outside hospitals with the need for novel CDI treatments becoming immediate. 25 The use of a single FMT infusion for rCDI was well documented. It soon became clear that in a minority of patients, especially those with severe CDI, multiple FMT treatments are required.
5,19,21,24,26
Fecal microbiota transplantation benefits and evolution of Clostridium difficile treatment FMT began with a crude liquid stool suspension, progressed to a filtered and frozen format, to frozen filtered capsules, and is now being produced as lyophilized powder within delayed-release capsules and encapsulated spore-specific combinations.
4,27,28
However, the danger of contamination or strain mutation and altered genotype expression is a constant risk for culture-derived product. An understated boon relating to FMT treatment is the availability of the source material. For patients suffering from CDI who are lacking ready access to FMT treatment, a number of sources offer information on home, "do-it-yourself" FMT instructions.
4 While these options are "low-cost", they do not provide the standardized protocols such as those offered by accredited health care facilities, extensive testing of donor stool, patient support and care, and access to professionals that administer both treatment and knowledge on FMT use. Hence, it is important that a either 50 ml of FMT via enema (n = 38) or 50 ml of water enema (n = 37) once weekly for 6 weeks. By week 7, 9 of 38 patients on FMT (24%) and 2 of 37 patients on placebo (5%) were in remission (P <0.03). A small study including 4 children with moderate-to-severe UC treated with 8 FMT infusions of 50 ml over 14 days found only transient improvement of symptoms, with poor long-term remission. 38 We can already see from these early results that FMT methods applied to the treatment of CDI do not work for IBD and the endpoints are different. In CDI, the endpoint is abolition of diarrhea and eradication of Clostridium difficile. Since there is no recognizable pathogen to eradicate in UC, the treatment endpoints can include response or remission (or both). Furthermore, 1 or 2 FMT treatments can cure most patients with relapsing CDI, whereas repeated infusions of FMT are required to achieve remission in UC, and even then other factors appear to be operating, such as donor differences. 37 Therefore, research on FMT in IBD will need to address the different pathophysiology in UC versus that in CDI.
Fecal microbiota transplantation and other gut disorders There is some provocative evidence for the use of FMT in other gut disorders, albeit the data are scant and generally confined to small cohort studies and case reports addressing such conditions as constipation, irritable bowel disease, IBS, pouchitis, and Crohn disease. 34, [39] [40] [41] [42] [43] There are multiple trials currently underway to examine the potential benefits of FMT in such conditions and these are listed on ClinicalTrials. gov at the time of writing (tAbLe 2).
Fecal microbiota transplantation and nongastrointestinal diseases There has been considerable interest in FMT for nongastrointestinal disorders in neurobehavioral disorders, which entail the connection between the gut and brain (gut-brain axis) and, more recently, the fecal microbiota and the brain. 44, 45 Most studies encompassing FMT and nongastrointestinal disease have focused on autism spectrum disorder (ASD). Patients with ASD commonly have gastrointestinal system disorders, and a correlation between the severity of ASD symptoms and gastrointestinal symptoms has been demonstrated. 46, 47 Patients with ASD have been shown to have alterations in the fecal microbiome, compared with patients without ASD. The presence of aberrant Clostridia species has been the most reported. 48 Restoration of the normal microbiome has been attempted with prebiotics, probiotics, and antibiotics with varying success, while treatment with nonabsorbable vancomycin provides a short-term improvement, suggesting the microbiome activates bioactive molecules that may be reaching the brain to cause ASD behavior. 49 Evidence for the use of FMT for ASD is emerging, and a small cohort study has been reported as an abstract. 50 Other neurological
Indications for fecal microbiota transplantation beyond
Clostridium difficile infection FMT has been suggested as a therapy for other non-CDI gastrointestinal conditions as well as many nongastrointestinal conditions. Some of these have already been reviewed. 21, 28, 33 Fecal microbiota transplantation and ulcerative colitis Apart from CDI, there is a high level of interest in FMT use as a potential therapy targeting IBD. It has been postulated that an aberrant mucosal reaction to gastrointestinal microbiota contributes to the pathogenesis of IBD although an alternative view is that an abnormal gut microbiota, or a dysbiosis, initiates the inflammatory process.
The first patient to receive FMT at our facility was in 1988, and she had indeterminate colitis without CDI. Her colitis completely disappeared and has not recurred over the past 27 years of follow-up. 34 We then reported further sporadic cases of ulcerative colitis (UC) responding to FMT.
35 FMT has been investigated in a number of cohort studies with variable results. Unlike CDI, the use of FMT in UC can result in transient improvement but only very occasionally-in a cure. A recent controlled study randomized 50 patients with mild-to-moderate UC of variable duration and used FMT via a nasoduodenal tube infusing either donor stools or autologous stool at 0 and 3 weeks. 36 Per-protocol "response rates" (clinical remission and ≥1 point decrease in the Mayo score) were 41.2% and 25%, respectively (P = 0.29). Moayyedi et al 37 reported a significant induction of remission in 75 patients receiving conditions of note that show the potential for treatment with FMT include the Parkinson disease and multiple sclerosis. 51, 52 It has also been suggested that the gastrointestinal microbiome plays a role in the pathogenesis of metabolic conditions. Changes in the gut microbiome have been reported in type 2 diabetes, and FMT has been demonstrated to improve insulin sensitivity in male patients with metabolic syndrome. 53, 54 Alterations in the microbiome have also been demonstrated in inflammatory conditions such as rheumatoid arthritis, in autoimmune disease, neurodevelopmental disorders, psychiatric diseases, and skin conditions. 45, [55] [56] [57] [58] conclusions Currently, the practicing physician should be aware that FMT for relapsing CDI has evolved from being an experimental treatment to an accepted life-saving therapy. In many countries, leading hospitals are developing FMT capability in the subspecialty of gastroenterology and infectious diseases. It needs to be stressed that the higher mortality epidemic strains such as 027 may drive the patient rapidly towards hypotension and renal failure, and an early referral to an FMT center is advisable. There is an active development of FMT products by biotech companies, and encapsulated treatment for CDI is likely to become available, permitting earlier and simpler therapy and obviating the need for the use of fecal suspension.
The use of FMT in conditions other than CDI is at present experimental but early reports point to potentially exciting changes in the way we will treat IBD, IBS, and possibly a number of other conditions. Research in such conditions is encouraged.
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